回购，正在逼“死”一部分医疗企业

Core Viewpoint - The "buyback" issue has become a significant concern in the venture capital industry, particularly affecting medical companies, leading to a survival crisis for many of them [2][3]. Group 1: Impact of Buybacks on Medical Companies - Ji Kai Gene, led by scientist Cao Yueqiong, faced legal action due to an inability to repay 227 million yuan in buyback debt, highlighting the severe consequences of buyback obligations [2]. - Other medical companies, such as Si Microbiology and Zhiben Medical, have also suffered from buyback pressures, resulting in operational halts and bankruptcy [2][3]. - A report indicates that approximately 130,000 projects involving around 14,000 companies, many in the medical sector, will soon face exit pressures due to buyback obligations [2]. Group 2: Misuse of Buyback Agreements - The buyback mechanism, initially intended to protect investors, has been misused in China, with its application rate in private equity projects reaching 80% to 90%, creating a coercive financing environment [7][8]. - The original intent of buyback clauses was to ensure company growth without harming operations, but the reality often leads to aggressive legal actions against founders, resulting in a high percentage of them being labeled as dishonest executors [8][9]. - The average recovery rate for buyback cases entering judicial proceedings is only 6%, indicating that even with buyback clauses, investors may not recover their investments [11]. Group 3: Recommendations for Improvement - Medical companies should avoid external capital if they can sustain themselves, focusing on risk management and understanding their capabilities before entering buyback agreements [11][12]. - Investment institutions should adopt reasonable terms in buyback agreements, avoiding excessive demands that could jeopardize the company's survival [12][13]. - The industry should explore alternative exit strategies to alleviate the pressure caused by buybacks, as the current environment has led to a vicious cycle of financial distress [13][14].